145441-17-4

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Isoxazolecarboxylic acid, 5-acetyl(9CI) is used as a building block for the preparation of other active pharmaceutical ingredients. Its unique structure allows it to be incorporated into various drug molecules, enhancing their therapeutic properties and effectiveness.
Used in Research Applications:
3-Isoxazolecarboxylic acid, 5-acetyl(9CI) is utilized in various research applications, including the development of new drugs and the study of biological processes. Its potential biological activity makes it a promising candidate for further investigation and exploration in the scientific community.
Used in the Treatment of Diseases and Disorders:
3-Isoxazolecarboxylic acid, 5-acetyl(9CI) has been studied for its potential therapeutic uses in the treatment of various diseases and disorders. Its unique properties and potential biological activity make it a valuable compound for the development of new treatments and therapies.

InChI:InChI=1/C6H5NO4/c1-3(8)5-2-4(6(9)10)7-11-5/h2H,1H3,(H,9,10)

Upstream product

• 104776-70-7 ethyl 5‐acetylisoxazole‐3‐carboxylate 

Downstream Products

• 139297-29-3 N-(2,6-dimethylphenyl)-5-acetyl-3-isoxazolecarboxamide 

Relevant academic research and scientific papers

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

ANDROGEN RECEPTOR MODULATING COMPOUNDS

Compounds of formula (I) wherein R1 to R16, A. B and E are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

New N-aryl isoxazolecarboxamides and N-isoxazolylbenzamides as anticonvulsant agents

We prepared a series of N-aryl isoxazolecarboxamide, N-isoxazolylbenzamide compounds and derivatives and studied their anticonvulsant action in MES and MMS tests. Some of these reveal considerable activity, especially with respect to MES test. The disubstitution in the 2.6-position on the phenyl ring by two methyl groups would appear to be of primary importance for the activity. The amide bridge between the phenyl and isoxazolic rings, whether of the anilide or benzamide type, seems to show similar anticonvulsant behavior. We have selected the derivatives 8 (N-(2.6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide, 12 (N-(2.6-dimethylphenyl)-5-hydroxymethyl-3-isoxazolecarboxamide) and 51 (N-(5-methyl-3-isoxazolyl)-2.6-dimethylbenzamide) which are presently being studied in more extended pharmacological tests.